Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure
Phase II Misses Could Benefit BMS’s Cobenfy
With two misses for emraclidine, AbbVie will hope to extract some value from the Cerevel acquisition from the Parkinson’s drug tavapadon, while BMS may get a big lead in the schizophrenia space.
